Gilead Sciences Inc

NASDAQ: GILD
$92.65
+$1.30 (+1.4%)
Real Time Data Delayed 15 Min.

GILD Articles

Out of all the biotechs that reported earnings last week, Gilead Sciences seems to be the one that hasn’t been taking its medicine in 2017.
Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings,...
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some buzz for Gilead.
Sometimes it turns out that great growth companies eventually run into the day when getting the growth of the past is not possible. That has been the case of Gilead Sciences since 2015.
The September 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Gilead, Johnson & Johnson, Potash, Schlumberger, Visa and Walmart.
The top analyst upgrades, downgrades and other research calls from Thursday include CarMax, DowDuPont, Gilead Sciences, GrubHub, Microsoft, Nike and Western Digital.
The top analyst upgrades, downgrades and other research calls from Wednesday include Freeport-McMoran, Gilead Sciences, FuelCell, Oracle, Take-Two Interactive, Tesla and Waste Management.
Thursday was a relatively mixed day for the U.S. broad markets. Although all the major averages started off negative a couple actually turned a gain on the day. Crude oil gave some back today and at...
The September 15 short interest data have been compared with the previous report, and short interest in all the selected biotech stocks increased.
The August 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The include Abercrombie & Fitch, Arch Coal, Baker Hughes, BioMarin Pharmaceutical, Gilead Sciences, Hasbro and Snap.
Gilead Sciences shares have been in a holding pattern for a while. Analysts have said that the firm needs to make a move to shake this situation, otherwise this could turn into something worse.